德玛塔疗愈公司美股招股说明书(2025-11-07版)

Up to $1,792,315 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated November 25, 2022, filed as apart of our registration statement on Form S-3 (File No. 333-268383) (the “Registration Statement”), as supplemented by ourprospectus supplements, dated June 7, 2024 and August 2, 2024 (collectively, the “Prior Prospectus”), relating to the offering, issuanceand sale by us of our common stock, par value $0.0001 per share (“Common Stock”), from time to time that may be issued and soldunder the at the market offering agreement (the “Sales Agreement”), dated June 7, 2024, by and between us and H.C. Wainwright &Co., LLC (“Wainwright”), as sales agent. This prospectus supplement should be read in conjunction with the Prior Prospectus, and isqualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in thePrior Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, thePrior Prospectus, and any future amendments or supplements thereto. We are filing this prospectus supplement to amend the Prior Prospectus to update the maximum amount of shares we areeligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. As a result of these limitations andthe current public float of our Common Stock, and in accordance with the terms of the Sales Agreement, we may offer and sell sharesof our Common Stock having an aggregate offering price of up to $1,792,315 from time to time through Wainwright, which does notinclude the shares of Common Stock having an aggregate sales price of approximately $1,662,142 that were sold pursuant to the PriorProspectus to date. In the event that we may sell additional amounts under the Sales Agreement and in accordance with GeneralInstruction I.B.6, we will file another prospectus supplement prior to making such additional sales. As of the date of this prospectus supplement, the aggregate market value of our outstanding Common Stock held by non-affiliates (the “public float”), was approximately $5,376,945, which was calculated based on 910,575 shares of our outstandingCommon Stock held by non-affiliates at a price of $5.905 per share, the closing price of our Common Stock on the Nasdaq CapitalMarket on September 16, 2025. During the twelve (12) calendar months prior to and including the date of this prospectus supplement,we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3. Pursuant to General Instruction I.B.6 of Form S-3,in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12 calendar-month period so long as our public float remains below $75.0 million. In the event that we may sell additional amounts under theSales Agreement, we will file another prospectus supplement prior to making such additional sales. We are an “emerging growth company” as defined in Section 2(a) of the Securities Act and a smaller reporting company asdefined under Rule 405 of the Securities Act, and as such, we have elected to comply with certain reduced public company reportingrequirements. See ‘‘Prospectus Supplement Summary— Implications of Being an Emerging Growth Company and a SmallerReporting Company” on page S-4 of the Prior Prospectus. Our Common Stock is listed on the Nasdaq Capital Market under the symbol “DRMA.” On November 6, 2025, the lastreported sale price of our Common Stock on the Nasdaq Capital Market was $2.95 per share. Investing in the offered securities involves a high degree of risk. Before buying any shares, you should read thediscussion of material risks of investing in our Common Stock in “Risk Factors” beginning on page S-6 of the PriorProspectus, and in the risks discussed under similar headings in the documents incorporated by reference in this prospectussupplement and the Prior Prospectus, as they may be amended, updated or modified periodically in our reports filed with theSecurities and Exchange Commission. NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSIONHAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACYOF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS. ANY REPRESENTATION TOTHE CONTRARY IS A CRIMINAL OFFENSE. H.C. Wainwright & Co. The date of this prospectus supplement is November 7, 2025